Sign In
Buy CCCC
$3.48
-0.180 (-4.92%)
At Close: Jul 31, 2026
C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Misses Revenue Estimates
09:16am, Thursday, 07'th Aug 2025
C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to a loss of $0.26 per share a year ago.
C4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
07:00am, Thursday, 07'th Aug 2025
Cemsidomide Phase 1 Data in Multiple Myeloma Accepted as an Oral Presentation at the International Myeloma Society (IMS) Annual Meeting; As of the July 23, 2025, Data Cutoff, Phase 1 ORR Remains at
C4 Therapeutics: An Entry Point If There's Ever Going To Be One
01:50pm, Monday, 16'th Jun 2025
CCCC's valuation is unjustifiably low, trading at half its liquidity despite a promising pipeline and no imminent cash crisis. Lead candidate cemsidomide shows encouraging early efficacy and tolerabil
C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Tops Revenue Estimates
09:15am, Wednesday, 07'th May 2025
C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $0.41 per share a year ago.
C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
07:00am, Wednesday, 07'th May 2025
Updated Cemsidomide Multiple Myeloma Data Further Demonstrate Compelling Response Rates at Multiple Doses and Potential for Best-in-Class Profile; 50% ORR Observed at the Highest Dose Level of 100 µ
C4 Therapeutics (CCCC) Loses -21.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
10:35am, Monday, 03'rd Mar 2025
C4 Therapeutics (CCCC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings est
C4 Therapeutics (CCCC) Loses -26.18% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
10:35am, Thursday, 27'th Feb 2025
The heavy selling pressure might have exhausted for C4 Therapeutics (CCCC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street ana
C4 Therapeutics, Inc. (CCCC) Reports Q4 Loss, Lags Revenue Estimates
09:20am, Thursday, 27'th Feb 2025
C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.68 per share a year ago.
C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
07:00am, Thursday, 27'th Feb 2025
Planning Activities Are Ongoing for Next Phase of Cemsidomide Clinical Development in Multiple Myeloma and Non-Hodgkin's Lymphoma; Trials Expected to Initiate in Early 2026
C4 Therapeutics (CCCC) Loses -23.14% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
10:36am, Wednesday, 26'th Feb 2025
The heavy selling pressure might have exhausted for C4 Therapeutics (CCCC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street ana
C4 Therapeutics to Participate in Upcoming March Investor Conferences
07:00am, Monday, 24'th Feb 2025
WATERTOWN, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science,
Here's Why C4 Therapeutics (CCCC) Is a Great 'Buy the Bottom' Stock Now
11:07am, Thursday, 02'nd Jan 2025
C4 Therapeutics (CCCC) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could me
In Multiple Myeloma, Cemsidomide in Combination with Dexamethasone at Highest Dose Level Explored to Date Achieved 36 Percent Overall Response Rate (ORR) and 45 Percent Clinical Benefit Rate (CBR); Re
C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors
07:00am, Wednesday, 20'th Nov 2024
Hoerter Brings Over Three Decades of Oncology Commercialization and Leadership Experience Appointment Underscores Continued Transformation of Board to Lead C4T into Next Phase of Pipeline Progress WAT
C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Tops Revenue Estimates
09:20am, Thursday, 31'st Oct 2024
C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.55 per share a year ago.
